rethinkTHC Search
Menu
Study breakdown

Comprehensive guide to Epidiolex (CBD) for treating childhood epilepsy

ReviewStrong evidence
The takeaway

Epidiolex, the first FDA-approved plant-derived CBD medication, significantly reduces seizures in Dravet and Lennox-Gastaut syndromes but has important side effects and drug interactions that require careful management.

Parents of children with refractory epilepsy, neurologists, and pharmacists.

First FDA-approved plant-derived CBD medication

What the researchers found

Epidiolex was FDA-approved June 2018 for patients aged 2+ with Dravet or Lennox-Gastaut syndrome. Common side effects include somnolence, decreased appetite, and diarrhea. Significant drug interactions occur with clobazam (increased active metabolite levels) and valproate (hepatotoxicity risk). CBD is metabolized primarily by CYP3A4 and CYP2C19, creating numerous potential interactions with other antiepileptic drugs.

Why it matters

Patients with Dravet and Lennox-Gastaut syndromes have limited treatment options. Understanding both the benefits and the interaction risks of Epidiolex is essential for safe prescribing.

The numbers in context

FDA approved June 25, 2018. Approved for ages 2+. Metabolized by CYP3A4 and CYP2C19. Significant interactions with clobazam and valproate.

How the study worked

State-of-the-art review covering CBD history, pharmacology, toxicology, clinical evidence, side effects, and drug-drug interactions in epilepsy.

What this study cannot tell us

Limited long-term efficacy and safety data. Drug interaction studies are ongoing. Review reflects knowledge at time of publication.

How to read the evidence

Comprehensive review of randomized controlled trial data supporting FDA approval.

When this study was published

2020 review of product approved in 2018.

The bigger picture

As the first plant-derived CBD product with FDA approval, Epidiolex bridges the gap between medical cannabis and conventional pharmaceuticals, but its complex interactions highlight the importance of pharmaceutical oversight.

Questions still open

  • Will long-term CBD use in children reveal new safety concerns? Can dosing strategies minimize hepatotoxicity risk when combined with valproate?

Common questions

What is Epidiolex used for?
Epidiolex is an FDA-approved purified CBD medication for patients aged 2 and older with Dravet syndrome or Lennox-Gastaut syndrome, two severe forms of childhood epilepsy.
Does Epidiolex interact with other seizure medications?
Yes, significant interactions occur with clobazam (increasing sedation) and valproate (increasing liver toxicity risk). CBD is metabolized by CYP3A4 and CYP2C19, creating potential interactions with many other drugs.

Read the original research

Emerging Use of Epidiolex (Cannabidiol) in Epilepsy.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 25(6), 485-499

Citation

Abu-Sawwa, Renad; Scutt, Brielle; Park, Yong. (2020). Emerging Use of Epidiolex (Cannabidiol) in Epilepsy.. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 25(6), 485-499. https://doi.org/10.5863/1551-6776-25.6.485

Explore the wider topic